Amaryl- M is an orally available combination anti-diabetic drug. The medicine contains two components – Glimepiride and Metformin. Metformin has a primary effect on reducing the release of glucose from the liver and decreases the amount of glucose that is absorbed from food. Glimepiride acts by lowering blood sugar by stimulating the release of insulin by pancreatic beta cells and by inducing increased activity of intracellular insulin receptors. Glimepiride acts selectively hence there are lowered episodes of hypoglycemia (one of the side effect). The combination is prescribed for patients suffering from type-2 diabetes which arises when the body is not able to use insulin effectively.
Amaryl -M is a brand marketed by Sanofi pharmaceuticals. Sanofi is an MNC which has been operational in the Indian pharma market since 1956. It’s been known for its oath breaking research molecules with strong scientific backup for the clinicians. Sanofi has always been pioneered operations in segments like cardio diabetic, oncology, CNS drugs etc.
Your doctor may have prescribed Amaryl -M because you could be suffering from Type II Diabetes.
Diabetes occurs when your blood glucose (blood sugar) is too higher than normal. Blood glucose is the main source of energy and it comes from carbohydrates which you consume through food. The pancreas produces a hormone called insulin, which helps convert the glucose from your food to energy by carrying it into your cells for functioning.
In a diabetic patient, body doesn’t produce enough insulin or doesn’t manage insulin well. Glucose then accumulates in your blood and doesn’t reach your cells causing a host of complications that may include, heart, eye, nervous system and kidney problems. Diabetes is mainly of 2 types, type -1 also called insulin dependent diabetes, type-2 non – insulin dependent diabetes. There is diabetes also seen in pregnancy at times known as gestational diabetes. Type- 1 diabetes is usually genetic in nature and is observed in young children hence also known as juvenile diabetes.
Today diabetes is catching up early in young adults in their 30’s too. Imbalanced diet (more junk food), stress at work as well as lack of enough exercise is making people prone to getting diabetic. India has been known the world wide as the diabetic capital for the sheer number of diabetics diagnosed each year. Teenage girls also today suffer from insulin resistance as part of the disorder PCOD which makes them pre-diabetic at times and needs rigorous control to prevent onset of diabetes early in life.
3 major symptoms of diabetes are excessive thirst, excessive hunger, and frequent urination .Diabetes is diagnosed by blood and urine tests. Blood tests are done to measure 2 components – fasting blood glucose (FBG) and post -prandial blood glucose (PPG) which is done after 2hours of having food. FBG value of <100mg/dl and PPG <140 mg/dl is normal range, any values above these are diabetic indicators. Sugar in urine is also indicator of diabetic patient. Confirmed diabetes are put on insulin regulating or excess glucose lowering medications. The blood sugar control post medications is mapped by a test called HbA1c which is done quarterly as the life cycle of the RBCs is 90-120 days. Ideal value of HbA1c below 7 needs to be achieved for blood sugar control.
Renal and hepatic impairment. Avoid alcohol consumption. Hypoglycaemic episodes.
Contraindicated in pregnancy. Contraindicated in lactation. Hypersensitivity diabetic ketoacidosis (DKA); renal dysfunction; CHF (CHF), patients undergoing radiological studies; acute or chronic metabolic acidosis. Pregnancy, lactation.
Concomitant admin with propranolol increases Cmax, AUC, and T1/2 of glimepiride. Aspirin increases the mean AUC of glimepiride. Furosemide increases the Cmax of metformin.
Potentially Fatal: NSAIDS, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid, MAOs, and beta blockers potentiate the hypoglycemic action of glimepiride.
Mechanism of Action
Glimepiride stimulates the insulin release from functioning pancreatic β-cells and inhibits gluconeogenesis at hepatic cells. It also increases insulin sensitivity at peripheral target sites. Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilisation).
If you are a healthcare practitioner and want additional material on the brand, disease, or molecule we have a few articles that can be hand-delivered by the company representative to you directly.